12 hours ago
1
hapabapa
Alnylam Pharmaceuticals (NASDAQ:ALNY) announced on Saturday that the company and its partner Roche (OTCQX:RHHBY) would begin a late-stage trial for its experimental heart disease therapy, zilebesiran, later this year, despite a mid-stage trial setback for the injectable.
Presenting data from
English (US) ·